The Company and Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended			24 Months Ended
	Dec. 31, 2021 EUR (€) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares	Dec. 31, 2020 USD ($) shares	Dec. 31, 2021 USD ($) shares
Accumulated deficit			$ (93,020,000)	$ (93,020,000)	$ (97,750,000)
Current liabilities exceeding current assets | €	€ 66,753,000
Convertible debt | €	€ 64,110,000
Preferred stock shares authorized | shares	5,000,000		5,000,000	5,000,000	5,000,000
Potentially shares issuable | shares	766,180,633	766,180,633	729,580,955
Sub award grant revenue USD		$ 1,825
Sub award grant revenue euro		1,602
Total grant revenue		5,930,000
Sub award project cost USD		510
Sub award project cost euro		428
Project cost		$ 8,850,000
Weighted-average shares outstanding, basic and diluted | shares	303,757,622	303,757,622	303,757,622	303,757,622
Grant Revenue [Member]
Concentration risk percentage	99.00%	99.00%	95.00%
NIH [Member]
Grant revenue | €	€ 1,547,000
First Year [Member]
Sub award project cost USD		$ 547
Sub award project cost euro		542
Project cost		1,940,000
Grant revenue		1,190,000
Second Year [Member]
Sub award project cost USD		870
Project cost		1,856,000
Grant revenue		1,052,000
Third Year [Member]
Sub award project cost USD		1,078
Project cost		1,720,000
Grant revenue		$ 1,078,000
Stock Option [Member]
Potentially shares issuable | shares	25,750,000	25,750,000	25,750,000
Convertible Loans [Member]
Potentially shares issuable | shares	740,430,633	740,430,633	703,830,955